Clinical trials: Severe Psoriasis
Psoriasis
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
The purpose of this study is to evaluate the safety and tolerability of long-term administration of etanercept in adults with psoriasis who have participated in previous etanercept psoriasis studies.
- Trial name
- NCT00111436
- Testing
- Etanercept
- Volunteers
- 912 people
- Sponsor
- Amgen
Plaque Psoriasis
A Phase 3 Clinical Study of QL2106 Injection
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis.
- Trial name
- NCT07511647
- Testing
- QL2106 injection, Tremfya®
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Psoriasis
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
This non-interventional, prospective, multi-center study aims to provide short- and long- term treatment patterns, effectiveness, and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis (with and…
- Trial name
- UNMASK2 (NCT04894890)
- Testing
- secukinumab
- Where
- 42 sites in China
- Volunteers
- 1,002 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis
Vitamins modulating homocysteine affect both TNF-alpha, vascular endothelial growth factor, and theoretically enhance the anti-inflammatory version of NOS thus hopefully increasing the efficacy and reducing the chance of some…
- Trial name
- NCT01704599
- Testing
- Humira Then Humira plus 3 B vitamins
- Volunteers
- 8 people
- Sponsor
- Wayne State University
Moderate-to-Severe Plaque Psoriasis
A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
This is study designed to investigate the efficacy and safety of Jaktinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and…
- Trial name
- PSO (NCT04612699)
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Moderate to Severe Plaque Psoriasis
A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT06943950
- Testing
- SYHX1901
- Volunteers
- 500 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Psoriasis, Moderate to Severe Plaque Psoriasis
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
This is a randomised, double-blind, multicentre clinical study to evaluate the efficacy, safety, tolerability, PK, and immunogenicity of SB17 compared to Stelara® in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT04967508
- Testing
- Stelara® (Ustekinumab), SB17 (Proposed Ustekinumab Biosimilar)
- Where
- 32 sites in Czechia, Estonia and 6 more
- Volunteers
- 503 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Plaque Psoriasis Patients
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
- Trial name
- NCT06842199
- Testing
- ICP-488 Tablets
- Where
- 46 sites in China
- Volunteers
- 383 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Palmoplantar Pustulosis
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis…
- Trial name
- NCT07013201
- Testing
- Delgocitinib cream, Vehicle cream
- Where
- 40 sites in United States, Canada and 3 more
- Volunteers
- 135 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
- Trial name
- BDS1307 (NCT02070965)
- Testing
- DFD01 Spray, Comp01 Lotion
- Where
- 12 sites in United States
- Volunteers
- 75 people
- Sponsor
- Primus Pharmaceuticals
Chronic Plaque Psoriasis
Chronic Plaque Psoriasis (Ps) Registry
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
- Trial name
- NCT00799877
- Where
- 339 sites in United States, Austria and 12 more
- Volunteers
- 6,065 people
- Sponsor
- AbbVie
Psoriasis
Study to Evaluate Broadlumab vs Placebo and Ustekinumab
The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
- Trial name
- AMAGINE-3 (NCT02786732)
- Testing
- 210mg Brodalumab, 140mg Brodalumab, Ustekinumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MedDerm Associates
Psoriasis
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- X-PLORE (NCT01483599)
- Testing
- CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg)
- Where
- 40 sites in United States, Belgium and 3 more
- Volunteers
- 293 people
- Sponsor
- Janssen Inc.
Plaque Psoriasis
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3)
- Trial name
- INDUS-3 (NCT04855721)
- Testing
- AUR101
- Where
- 25 sites in United States
- Volunteers
- 141 people
- Sponsor
- Aurigene Discovery Technologies Limited
Chronic Plaque Psoriasis
TRUST Study: Raptiva ® in Hand & Foot Psoriasis
To evaluate the safety and efficacy of Raptiva ® compared with placebo to control chronic moderate to severe plaque psoriasis involving the hands and/or feet scoring Physician's Global Assessment (PGA - H\&F) greater-than or…
- Trial name
- TRUST (NCT00739882)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Psoriasis
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT01208090
- Testing
- ACT-128800
- Where
- 67 sites in Austria, Belgium and 15 more
- Volunteers
- 326 people
- Sponsor
- Actelion
Plaque Type Psorisis
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis
- Trial name
- SUPREME (NCT02394561)
- Testing
- Secukinumab
- Where
- 45 sites in Italy
- Volunteers
- 434 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque-type Psoriasis
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
This was an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab.
- Trial name
- NCT01544595
- Testing
- Secukinumab (AIN457)
- Where
- 182 sites in United States, Argentina and 24 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
This study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group.
- Trial name
- NCT07724366
- Testing
- TQH3906 capsules, Deucravacitinib tablets 6 mg
- Where
- 45 sites in China
- Volunteers
- 400 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.